Benefits of [68Ga]-DOTATATE PET-CT comparable to [18F]-FDG in patient with suspected cardiac sarcoidosis

Vachatimanont, Sira; Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Chotipanich, Chanisa

doi:10.1007/s12350-020-02303-0

Cited by 8 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded SSTR PET may be more specific for acute inflammation and bear a potential role in treatment response. Other earlier or smaller studies demonstrated similar or improved performance of SSTR-PET tracers compared with [ 18 F]FDG [ 26 , 27 , 28 , 29 , 30 ]. A case of neurosarcoidosis imaged with [ 68 Ga]Ga-DOTATATE was reported by Unterrainer et al [ 31 ].…”

Section: Discussionmentioning

confidence: 87%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

Somatostatin receptor (SSTR) agonist tracers used in nuclear medicine scans are classically used for neuroendocrine tumor diagnosis and staging. SSTR are however, expressed more widely in a variety of cells as seen in the distribution of physiological tracer uptake during whole body scans. This provides opportunities for using these tracers for applications other than NETs and meningiomas. In this qualitative systematic review, novel diagnostics in SSTR-PET imaging are reviewed. A total of 70 studies comprised of 543 patients were qualitatively reviewed. Sarcoidosis, atherosclerosis and phosphaturic mesenchymal tumors represent the most studied applications currently with promising results. Other applications remain in progress where there are many case reports but a relative dearth of cohort studies. [18F]FDG PET provides the main comparative method in many cases but represents a well-established general PET technique that may be difficult to replace, without prospective clinical studies.

show abstract

Section: Discussionmentioning

confidence: 87%

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The mediastinal lymphadenopathy demonstrated only mild DOTATATE uptake, suggesting against carcinoid involvement (Krenning 2). Sarcoid granulomas have been shown to express somatostatin receptors in prior reports using DOTATATE imaging 4,5. The patient later declined mediastinal tissue biopsy.…”

mentioning

confidence: 90%

“…Sarcoid granulomas have been shown to express somatostatin receptors in prior reports using DOTATATE imaging. 4,5 The patient later declined mediastinal tissue biopsy. PET and corresponding CT images (A and B), without abnormal FDG uptake in the myocardium (not shown).…”

mentioning

confidence: 99%

The “Ultimate Triple PET”

McClenathan

Peacock

2021

Clin Nucl Med

View full text Add to dashboard Cite

A 71-year-old man with a history of carcinoid and prostate adenocarcinoma underwent 68 Ga-DOTATATE PET/CT to evaluate new mediastinal lymphadenopathy. The scan revealed new carcinoid metastases, but the mediastinal nodes were not avid. 18 F-FDG PET/CT was performed to evaluate for cardiac and mediastinal sarcoidosis, revealing a lack of cardiac sarcoidosis, but probable mediastinal sarcoidosis. 18 F-Fluciclovine PET/CT was then performed for possible prostate metastases, revealing the patient's known prostate cancer. Three different PET radiopharmaceuticals revealed 3 different processes in a single patient within a 195-day period, demonstrating the power of nuclear medicine diagnostics.

show abstract

Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers

Shi

Miller

2023

Curr Cardiovasc Imaging Rep

View full text Add to dashboard Cite

Benefits of [68Ga]-DOTATATE PET-CT comparable to [18F]-FDG in patient with suspected cardiac sarcoidosis

Cited by 8 publications

References 3 publications

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors

The “Ultimate Triple PET”

Novel Radiotracers for Molecular Imaging of Myocardial Inflammation: an Update Focused on Clinical Translation of Non-18F-FDG Radiotracers

Contact Info

Product

Resources

About